Innovent begins Phase 1 Study of IBI321 for advanced malignant tumors

Chinese biopharmaceutical company Innovent Biologics Inc. announced to have dosed the first patient in the Phase 1 study of an anti-TIGIT and PD-1 bispecific antibody, IBI321.

This study aims to primarily analyze the tolerability, safety, potential optimal dosage, and efficacy of IBI321 in patients who have advanced solid tumors and have treated cancer through standardized treatment methods.

For the record, Innovent Biologics Inc. is a renowned biopharmaceutical company that specializes in the development, manufacturing, and commercialization of top-quality medicines for the treatment of metabolic and autoimmune disorders, cancer, and other major diseases.

The IBI321 is essentially a bispecific antibody that can improve efficacy by targeting both TIGIT and PD-1 synergistically. Preclinical studies of the antibody have shown that the anti-cancer efficacy of the antibody was higher as the molecule managed to suppress TIGIT while retaining the activity of a PD-1 inhibitor.

Moreover, it can also improve immune activation and raise the convenience of administration. In this context, the Chief of Respiration Department, Professor Baohui Han was quoted saying that although immune checkpoint inhibitors are highly effective in treating a variety of tumors, their efficacy rates still require to be enhanced.

Doctors still face challenges of secondary and primary drug resistance when treating advanced tumors and this can be reduced by the development of next-generation bispecific antibodies, the Professor added.

Dr. Hui Zhou the Senior VP of Clinical Development at Innovent Biologics reportedly said that IBI321 is designed to target both TIGIT and PD-1 and block their pathways by working in a synergetic manner. She further added that there is no other bispecific antibody with the same target as IBI231 currently in the clinical stage anywhere across the world.

The study is being conducted on patients between the age group of 18 to 75 years in China.

Source Credits—